Lisa Langlumé
Biographic Data
| ID | 7180857 |
|---|---|
| NAME | Lisa Langlumé |
| GIVEN NAMES | Lisa |
| FAMILY NAME | Langlumé |
| SIGNATURE | LANGLUMÉ L |
| AFFILIATIONS | Département de Pharmacologie Médicale Et Toxicologie, Centre d’Addictovigilance, Chu Montpellier, Univ Montpellier, Montpellier, France |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
Management of Pregabalin Use Disorder
Pregabalin is indicated for the treatment of partial epilepsy, generalized anxiety disorder, and neuropathic pain. The first reports on pregabalin use disorder have been published in Europe in 2010 and notified to the French Addictovigilance Network (FAN) in 2011. The management of pregabalin use disorder is challenging due to the risks associated with the abrupt withdrawal and lack of guidelines. In this retrospective observational study, the ma…
No prominent works on this page.
Management of Pregabalin Use Disorder
Pregabalin is indicated for the treatment of partial epilepsy, generalized anxiety disorder, and neuropathic pain. The first reports on pregabalin use disorder have been published in Europe in 2010 and notified to the French Addictovigilance Network (FAN) in 2011. The management of pregabalin use disorder is challenging due to the risks associated with the abrupt withdrawal and lack of guidelines. In this retrospective observational study, the ma…
Anxiety (1 works) · Generalized anxiety disorder (1 works) · Medicine (1 works) · Opioid Use Disorder Treatment (1 works) · Pain Mechanisms and Treatments (1 works) · Pharmacological Effects and Toxicity Studies (1 works) · Pregabalin (1 works) · Psychiatry (1 works)